Zhenyu Nie

Changsha, 410008, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Tro-score, a trogocytosis-related transcriptomic signature, identifies CD109 as a therapeutic target for reversing immunosuppression in bladder cancer.

Tro-score, a trogocytosis-related transcriptomic signature, identifies CD109 as a therapeutic target for reversing immunosuppression in bladder cancer.

Journal: International immunopharmacology

Published: June 20, 2026

Nuclear receptors meet natural sesquiterpenes: From preclinical mechanisms to therapeutic potential.

Nuclear receptors meet natural sesquiterpenes: From preclinical mechanisms to therapeutic potential.

Journal: European journal of pharmacology

Published: August 27, 2025

Overcoming immunotherapy resistance in bladder cancer with a novel antibody-drug conjugate RC48.

Overcoming immunotherapy resistance in bladder cancer with a novel antibody-drug conjugate RC48.

Journal: Journal for immunotherapy of cancer

Published: July 16, 2025

Long-term resident adipose-derived stromal stem cells in the microenvironment remodeling BLCA cell stemness and EMT promotes bladder cancer progression.

Long-term resident adipose-derived stromal stem cells in the microenvironment remodeling BLCA cell stemness and EMT promotes bladder cancer progression.

Journal: Scientific reports

Published: February 27, 2025

Efficacy and biomarker analysis of neoadjuvant disitamab vedotin (RC48-ADC) combined immunotherapy in patients with muscle-invasive bladder cancer: A multi-center real-world study.

Efficacy and biomarker analysis of neoadjuvant disitamab vedotin (RC48-ADC) combined immunotherapy in patients with muscle-invasive bladder cancer: A multi-center real-world study.

Journal: iMeta

Published: January 29, 2025

Evasion of immunosurveillance by the upregulation of Siglec15 in bladder cancer.

Evasion of immunosurveillance by the upregulation of Siglec15 in bladder cancer.

Journal: Journal of hematology & oncology

Published: September 27, 2024

Oncogenic ACSM6 impairs CD8+ T cell-based immune response in bladder cancer.

Oncogenic ACSM6 impairs CD8+ T cell-based immune response in bladder cancer.

Journal: Biomarker research

Published: July 22, 2024

Metal-Drug Coordination Nanoparticles and Hydrogels for Enhanced Delivery.

Metal-Drug Coordination Nanoparticles and Hydrogels for Enhanced Delivery.

Journal: Advanced materials (Deerfield Beach, Fla.)

Published: March 19, 2024

Author Correction: Duality of the SVIL expression in bladder cancer and its correlation with immune infiltration.

Author Correction: Duality of the SVIL expression in bladder cancer and its correlation with immune infiltration.

Journal: Scientific reports

Published: January 29, 2024

Machine learning-based on cytotoxic T lymphocyte evasion gene develops a novel signature to predict prognosis and immunotherapy responses for kidney renal clear cell carcinoma patients.

Machine learning-based on cytotoxic T lymphocyte evasion gene develops a novel signature to predict prognosis and immunotherapy responses for kidney renal clear cell carcinoma patients.

Journal: Frontiers in immunology

Published: March 23, 2023

Genome-Wide Screening Identifies Gene AKR1C1 Critical for Resistance to Pirarubicin in Bladder Cancer.

Genome-Wide Screening Identifies Gene AKR1C1 Critical for Resistance to Pirarubicin in Bladder Cancer.

Journal: Cancers

Published: March 13, 2023

Duality of the SVIL expression in bladder cancer and its correlation with immune infiltration.

Duality of the SVIL expression in bladder cancer and its correlation with immune infiltration.

Journal: Scientific reports

Published: February 19, 2023

Showing 1-12 of 22

Last Updated: 09/26/2026